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A variant antithrombin with reduced heparin affinity was shown by raass spectrometry sequencing and DNA amplification to have a substitution 
of a cysteine for an arginine at residue 24. The position of Arg-24 cart be fixed within a 12 A radius from the bridge at Cys-21. This is compatible 
with findings in the homologous protease nexin-1 which indicate an extension of the binding site of heparin from the D-helix to under the adjacent 
amino-terminal pole. 
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1. INTRODUCTION 2. MATERIALS AND METHODS 
Antithrombin, the major inhibitor of thrombin in 
human plasma, is a member of the serpin family of 
serine proteinase inhibitors. It shares with two other 
serpins, protease nexin 1 and heparin cofactor II, the 
requirement o bind sulphated polysaccharides in order 
to activate inhibition, with antithrombin increasing its 
association constant for thrombin 10 000-fold in the 
presence of heparin [1]. Comparison of the structures 
of the three serpins shows a shared homologous bind- 
ing site for heparin formed by basic residues and ex- 
tending from the commencement of the A helix to 
along the distal third of the D-helix I2-4]. Although 
there is good evidence that this is the common teleo- 
logical binding site, there is variation in the binding 
characteristics of the three serpins. In particular, there 
is strong evidence that the basic amino-terminal exten- 
sion, uniquely present in antithrombin, is also involved 
in the primary binding of heparin [5]. The precise rela- 
tionship of this N-terminal site in antithrombin to the 
shared site must await further crystallographic data, 
but preliminary evidence of the structural relationship 
of the two sites is provided from natural mutants of 
antithrombin. We present here a new low-heparin- 
affinity variant of antithrombin which indicates the in- 
volvement of residue Arg-24 in the N-terminal in the 
binding of heparin and we discuss the relationship of 
this residue to an extended common (D-helix) site. 
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2.1. Materials 
Antithrombin measurements in plasma, amplification of exon 2 of 
the antithromhin gene, and direct sequencing of the DNA product 
were carried out as recently detailed [6]. Oligonucleotides for exon 
2,5' (ATCTTTTGTCCTTGCTGCTAATTGGC) and 5' (CCATCA- 
GTTGCTGGAGGTGTCATTA), spanning positions 50-406 were 
synthesised on an Applied Biosystems Synthesiser and used in 
amplification reactions without purification. 
2.2. Heparin-Sepharose chromatography 
1 ml of 5 mM CaCl2 and 1 ml of 10070 dextran sulphate were added 
to 100 ml of plasma. The supernatant was applied to a 1.5 x 25 cm 
column of heparin-Sepharose equilibrated in 50 mM Tris-HCl, 
l0 mM citrate, pH 7.4 [3]. The column was eluted with a linear gra- 
dient to 1.3 M NaCl in the same buffer. 
2.3. Protein structure analysis 
Amithrombin was carboxyamidomethylated in 8 M urea [7] and 
digested with trypsin for 16 h at 37°C [8]. Reverse-phase HPLC map- 
ping was carried out using a Waters 8 mm i.d. radial compression 
cartridge with a 10/~m C-18 packing. The initial solvent (A) was 
49 mM KH2PO4 adjusted to pH 2.9 with orthophosphoric acid, 
while solvent B consisted of a 50:50 mixture of A in acetonitrile [8]. 
The flow rate was 1.5 ml/min and a linear gradient was run from 0070 
to 67070 B over 46 rain then to 100070 B over the next 8 min. 
Preparative separations employed Img (17 nmol) of digest. In- 
dividual peaks were collected and further purified by rechro- 
matography in a volatile ammonium acetate/acetonitrile solvent 
system [8]. 
Amino acid analysis was performed on a Dionex D-300 Analyser 
with ninhydrin detector. Mass spectrometry was performed on a 
VG70-2505 double-focusing magnetic sector instrument using a 
liquid secondary ion mode with caesium ions forming the primary ion 
[9]. 
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3. RESULTS 
3.1. Case history 
Plasma was obtained from a 25-year-old man who 
developed an unexpected coronary thrombosis. Subse- 
quent investigations showed two abnormalities; the 
presence of a heterozygous dysfunctional ntithrombin 
(described here) inherited from his father, and a 
hypofibrinogenaemia inherited from his mother. The 
single other instance of thromboembolic disease in the 
family had occurred in the mother's kinship; there was 
no history of thromboembolism from the father or his 
kinship. 
3.2. Antithrombin measurements in plasma 
Plasma from the propositus gave normal antigenic 
levels of antithrombin (105°70) and there was no impair- 
ment of slow (progressive) inhibitory activity against 
thrombin. However, the fast (heparin cofactor) activity 
against hrombin in the presence of heparin was re- 
duced to 57%. Electrophoresis in agarose gel at pH 8.6 
showed the presence of an abnormal band of an- 
tithrombin with increased overall negative charge. 
3.3. Heparin Sepharose chromatography 
Elution of plasma from heparin Sepharose gave two 
well-resolved peaks of anti-thrombin; one eluted in the 
normal position at 0.83 M NaCI, the other, the variant 
(Rouen-IV) peak, eluted at 0.45 M NaC1. Both peaks 
gave single bands Mr 58 000 on SDS-PAGE. The low- 
affinity (Rouen-IV) fraction separated anodally on 
agarose gel electrophoresis, indicating adecrease in net 
positive change. 
3.4. Protein structure analysis 
Reverse phase tryptic maps showed 3 clear and 
reproducible differences between digests of the normal 
and variant antithrombin components (Fig. 1). Anti- 
thrombin Rouen-IV lacked 3 of the tryptic peptides 
that were present in normal antithrombin at 8.5, 9.6 
and 22 min. Amino acid analysis of these normal peaks 
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Fig. 1. Reverse-phase tryptic peptide maps of carboxamidome- 
thylated anti-thrombin from the propositus. Lower trace, normal 
component; upper trace, antithrombin Rouen-IV. 
showed that they represented a jacent and overlapping 
sequences encompassing residues 21-29, Cys-Ile-Tyr- 
Arg-Ser-Pro-Glu-Lys-Lys. 
The 3 missing peaks in the digests of Rouen-IV are 
readily explicable in terms of mutation of Arg-24 to a 
neutral residue. As no new abnormal peak could be 
readily discerned in the HPLC trace, total tryptic 
digests were analysed by liquid secondary ion mass 
spectrometry [11]. New peptide signals were detected at 
mass 1057 and 1185. These values correspond to the 
masses of the protonated peptides C I Y C S P E K and 
C I Y C S P E K K with two carboxamidomethylated 
cysteine residues. These results indicate the mutation 24 
Arg --* Cys. 
3.5. DNA sequence analysis 
Direct sequence analysis of amplified DNA showed a
C ~ T mutation at nucleotide 166 giving a codon 
reading alteration 24 Arg (CGC) ~ Cys(TGC). 
4. DISCUSSION 
The DNA and protein sequence data show the pa- 
tient to be the heterozygous carrier of a new variant an- 
tithrombin arising from a point mutation causing a 
substitution of arginine-24 by cysteine. This loss of an 
arginine explains the observed anodal shift on elec- 
trophoresis as well as the decreased affinity on heparin- 
Sepharose and the decreased heparin-induced inhibi- 
tory activity. Antithrombin Rouen-IV is thus an addi- 
tion to the known heparin-affinity variants of anti- 
thrombin. By implication arginine-24 istherefore likely 
to be involved in the ionic bonding to the sulphate of 
the oligosaccharide and to form part of the heparin 
binding site. 
This would initially appear to be in conflict with cur- 
rent proposals as to the position of the site. There is 
good evidence [3,4] that the primary binding site for 
heparin is centred on the upper third of the D-helix 
(Fig. 2). The strongest evidence is the unique conserva- 
tion of this positively charged face of the D-helix in the 
three serpins activated by sulphated polysaccharides: 
antithrombin, protease nexin 1 and heparin cofactor II. 
However, the identified mutations of antithrombin af- 
fecting heparin affinity are mostly situated in the N- 
terminal portion of the molecule, particularly at Arg-47 
and Pro-41, raising the question of a possible second 
site. 
In fact, closer analysis of the results provides an ex- 
planation compatible with a unitary site. In the first 
place the frequency of observed mutants i a misleading 
index of the comparative contribution of different 
amino acids. The occurrence of CpG dinucleotides in
the codons for Arg-47 and Pro-41 explains the frequen- 
cy of mutants [10] at these residues as it does the muta- 
tion of the present variant at Arg-24. The comparative 
infrequency of variants of the basic residues of the D- 
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Fig. 2. Heparin binding site of antithrombin projected on the structure of cleaved antitrypsin; below right is schematic pentasaccharide h parin. 
The position of Arg-24 must lie within the 12 ,~ radius shown about Cys-21. Figure adapted from [4] which gives further details. 
helix is explained by the absence in their codons of CpG 
dinucleotides which will give rise to expressed substitu- 
tions. A second point is that although Arg-47 is near 
the amino-terminus it is also closely situated to the pro- 
posed common binding site. Its position can be reliably 
calculated since it is at the commencement of the A- 
helix present in the archetypal tertiary structures. On 
the model Arg-47 is adjacent to the base of the D-helix 
and is clearly seen to form part of the contiguous basic 
binding site [4]. This, however, is the limit of our 
present knowledge of the tertiary structure as positions 
proximal, i.e. amino-terminal, to the base of the A- 
helix are not yet defined on the model. At this stage we 
cannot determine the position of Arg-24 but the area 
within which it must lie can be calculated as being 
within a 12 A radius of the sulphydryl bridge formed by 
Cys-21, near the amino-terminal pole of the molecule 
(see Fig. 2). 
A clue to the overall extent of the heparin site is pro- 
vided by the model of protease nexin 1. This lacks a 
basic amino-terminal extension and also does not have 
an arginine at the base of the A-helix; protease nexin 1 
does, however, have extra basic residues which are seen 
on the model to substitute for Arg-47 and to provide an 
extension of charge towards the pole of the molecule 
and within the region of Arg-24. These extra positively 
charged residues, all within 12 ,~ of Cys-21, are in the 
C-helix at positions 53 Arg, 55 and 56 Lys and 63 Arg 
in protease nexin-1. This last residue, 63 Arg is ho- 
mologous to 107 Lys in antithrombin, implicated by 
Chang [111 as a binding site for heparin. In conclusion, 
we believe the weight of evidence favours a unitary 
primary heparin binding site extending from the lower 
third of the D-helix to under the adjacent (amino- 
terminal) pole of the molecule. This is compatible with 
the overall data from variant studies but the precise 
relationship of the folded N-terminus to the binding 
site in antithrombin must await crystallographic 
studies. 
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